Bayer's move leaves Merck still out in front – with an approval for gefapixant for cough in Japan where the drug is known as Lyfnua – but clearly casts a shadow on the class as a whole.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

European Union leaders said on Thursday that they will continue to support Ukraine, but they did not immediately endorse a call by Ukrainian President Volodymyr Zelenskiy to provide at least 5 ...

Bayer has filed for approval in the US for elinzanetant as a non-hormonal treatment for menopausal symptoms such as hot flushes, with a rival therapy from Astellas in its sights. The FDA ...